Search

Displaying results 6941 - 6950 of 9322 in total
  1. Drug

    Biropepimut-S

    go.drugbank.com/drugs/DB14816
    Investigational

    Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral

  2. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. … It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  3. Drug

    AMY-101

    go.drugbank.com/drugs/DB14803
    Investigational

    AMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3. … AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis).

  4. Drug

    SRP-9005

    go.drugbank.com/drugs/DB17958
    Investigational

    Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]

  5. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

  6. Drug

    TO-901317

    go.drugbank.com/drugs/DB07080
    Experimental

    TO-901317 is an LXRalpha and LXRbeta agonist.

  7. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

    Synonyms: (4S)-4-(4-CHLOROPHENYL)-1-((3E)-3-(9-(1-HYDROXY-1-METHYL-ETHYL)-5H-(1)BENZOXEPINO(3,4-B)PYRIDIN-11-YLIDENE)PROPYL)-3,3-DIMETHYL-PIPERIDIN-4-OL
  8. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  9. Drug

    Zeteletinib

    go.drugbank.com/drugs/DB21491
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Zeteletinib is a tyrosine kinase inhibitor.

  10. Drug

    Resomelagon

    go.drugbank.com/drugs/DB21579
    Investigational

    The usage of the INN stem '-melagon' in the name indicates that Resomelagon is a non-peptidic melanocortin receptor agonist.